SG10201800265UA - Anti-c5 antibodies and methods of use - Google Patents
Anti-c5 antibodies and methods of useInfo
- Publication number
- SG10201800265UA SG10201800265UA SG10201800265UA SG10201800265UA SG10201800265UA SG 10201800265U A SG10201800265U A SG 10201800265UA SG 10201800265U A SG10201800265U A SG 10201800265UA SG 10201800265U A SG10201800265U A SG 10201800265UA SG 10201800265U A SG10201800265U A SG 10201800265UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201800265UA true SG10201800265UA (en) | 2018-02-27 |
Family
ID=59969459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201800265UA SG10201800265UA (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
| SG11201705584VA SG11201705584VA (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705584VA SG11201705584VA (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (3) | JP6202774B1 (en) |
| KR (2) | KR101852739B1 (en) |
| CN (3) | CN115925922A (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (1) | PE20190394A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG10201800265UA (en) |
| TW (4) | TWI807666B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101463631B1 (en) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | Method for control of blood kinetics of antibody |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PL2708558T3 (en) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CN107207607B (en) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| TW202300168A (en) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Composition for prophylaxis or treatment of il-8 related diseases |
| JP2020536097A (en) * | 2017-10-04 | 2020-12-10 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Dosage and administration of anti-C5 antibody for the treatment of patients with membranous proliferative glomerulonephritis |
| CN111630065A (en) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | anti-C5 antibody combinations and uses thereof |
| MX2021002710A (en) * | 2018-09-06 | 2021-09-23 | Univ Pennsylvania | Humanized anti-c5 antibodies and uses thereof. |
| CN114072174A (en) * | 2019-04-24 | 2022-02-18 | 宾夕法尼亚大学理事会 | Dual-function humanized anti-C5 antibody and factor H fusion protein and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP1410671B1 (en) | 2001-06-12 | 2011-01-12 | TELEFONAKTIEBOLAGET LM ERICSSON (publ) | Synchronisation in a umts terrestrial radio access network (utran) |
| CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| EA200901211A1 (en) * | 2007-03-22 | 2010-04-30 | Новартис Аг | ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION |
| KR101515650B1 (en) | 2007-04-11 | 2015-04-27 | 세키스이가가쿠 고교가부시키가이샤 | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| PL2708558T3 (en) * | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2815766B1 (en) * | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| MX2012010481A (en) * | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING. |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| JP6309521B2 (en) * | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Anti-PCSK9 antibody with pH-dependent binding properties |
| CN105143261B (en) * | 2013-01-31 | 2021-04-09 | 首尔大学校产学协力团 | C5 antibodies and methods for preventing and treating complement-associated diseases |
| JP6505079B2 (en) * | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Compositions and methods for increasing the serum half-life of a therapeutic that targets complement C5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (en) * | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
| MY186948A (en) * | 2015-12-18 | 2021-08-26 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265800A (en) | Anti-lag-3 antibodies and methods of use thereof | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| PL3618863T3 (en) | Anti-tigit antibodies and methods of use thereof | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| IL263657A (en) | Anti-c5 antibodies and methods of use | |
| SG11201607165YA (en) | Anti-c5 antibodies and methods of use | |
| HK1251942A1 (en) | Anti-c5 antibodies and methods of use | |
| LT3601358T (en) | Anti-trem2 antibodies and methods of use thereof | |
| HK1259251A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| IL265957A (en) | Anti-c1s antibodies and methods of use thereof | |
| IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
| ZA202002144B (en) | Antibodies and methods of use |